What Cortagen Is
Cortagen is a synthetic tetrapeptide, Ala-Glu-Asp-Pro (AEDP), C17H26N4O9, 430.41 g/mol. Within the bioregulator family it is classified as brain-cortex derived, and it is one of the members with published work naming it.
What makes Cortagen worth reading closely is not the size of its literature but a tension inside it — one that bears directly on the family's central claim about tissue specificity.
Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists and no therapeutic claim is made.
What the Published Studies Report
Injured nerve function
A study in Doklady Biological Sciences reported a delayed effect of Cortagen on restoration of injured nerve function (Kolosova et al., 2002, PMID 12134478). The word "delayed" in the title is doing real work: the reported effect emerged over time rather than acutely, which shapes how any follow-up would need to be designed.
Chronic cerebral ischaemia
Work in Eksperimental'naia i Klinicheskaia Farmakologiia examined Cortexin and Cortagen as correcting agents in functional and metabolic disorders of the brain in chronic ischaemia (Zarubina & Shabanov, 2011, PMID 21476278). As with several papers in this family, the design pairs the tetrapeptide with a separate preparation, so effects cannot be assigned to Cortagen alone.
Gene expression — in heart
The most interesting entry is a microarray study elucidating the effect of the brain-cortex tetrapeptide Cortagen on gene expression in mouse heart (Anisimov et al., Neuro Endocrinol Lett 2004, PMID 15159690).
That is worth pausing on. A compound classified as cortex-associated was measured for transcriptional effects in cardiac tissue. Whatever the result, the choice of design implies the investigators did not treat tissue association as a constraint — which sits awkwardly beside the family's framing of each peptide as organ-specific. Anyone using the tissue-specificity claim as a premise should read this paper before relying on it.
Reading the Evidence
The literature is small and old. Three papers, the most recent from 2011, largely in Russian-language journals.
Two of three are combination or cross-tissue designs. That limits attribution more than the abstract count of papers suggests.
No amount is established for any species or context, because no controlled human programme exists.
Structure and Handling
- Sequence. Ala-Glu-Asp-Pro (AEDP), tetrapeptide.
- Formula. C17H26N4O9, 430.41 g/mol.
- Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
- Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
- Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.
Related Compounds
Pinealon (Glu-Asp-Arg) is the other CNS-associated member and has a somewhat larger literature. Vilon appears in the same early microarray line of work. See the bioregulator overview for the full family.
Comparative Sequence Analysis: Cortagen Among the Khavinson Tetrapeptides
Cortagen (Ala-Glu-Asp-Pro; AEDP) belongs to a family of synthetic tetrapeptides whose members are distinguished primarily by sequence, claimed tissue origin, and — where data exist — reported bioactivity. Aligning the published sequences reveals structural patterns worth noting for any researcher designing comparative assays.
| Peptide | Sequence | Claimed Tissue Origin | MW (g/mol) | Published PMIDs (examples) |
|---|---|---|---|---|
| Cortagen | Ala-Glu-Asp-Pro | Brain cortex | 430.41 | 12134478, 15159690, 21476278 |
| Epithalon | Ala-Glu-Asp-Gly | Pineal gland | 390.35 | 11349233, 12937682 |
| Vilon | Lys-Glu | Thymus | 275.30 | 15032359 |
| Cardiogen | Ala-Glu-Asp-Arg | Heart | 487.49 | See note |
Note: Cardiogen PMIDs were not verified at time of writing; investigators should conduct independent PubMed searches before relying on any citation for this compound. MW values for Cortagen and Epithalon computed from residue masses and confirmed against PubChem CID records.
The juxtaposition of Cortagen (AEDP) and Cardiogen (AEDR) is immediately apparent: they share the first three residues and differ only at position 4 (Pro vs. Arg). This is a meaningful structural question. Proline introduces a conformational constraint — its pyrrolidine ring restricts backbone dihedral angles and is frequently a helix-breaking residue in longer sequences. Arginine at the same position carries a guanidinium side chain capable of salt-bridge formation and, in some contexts, interaction with acidic residues in receptor binding pockets. Whether this single substitution is sufficient to produce the tissue-selective transcriptional profiles claimed for each peptide has not, to this reviewer's knowledge, been tested in a head-to-head binding or transcriptional assay. The cardiac microarray result for Cortagen[6] compounds this question: if AEDP produces detectable gene-expression changes in heart tissue, the mechanistic distance between it and the cardiac-classified AEDR may be smaller than the tissue-origin taxonomy implies. That is not a conclusion — it is an unresolved experimental question that the existing literature does not close.
Epithalon (AEDG) shares positions 1–3 with Cortagen and substitutes Gly at position 4, which, like Pro, lacks a substantial side chain but for entirely different steric reasons. Epithalon has a comparatively larger published record, including telomerase-related work in cell culture, but cross-compound inference is not supported: different C-terminal residues in short peptides can produce distinct conformers with distinct receptor contact surfaces. Sequence similarity is not pharmacological equivalence, and researchers designing assays involving more than one member of this family should treat each compound as independent until direct comparative data exist.
Epistemic Audit: What the Three Published Studies Can and Cannot Establish
The Cortagen literature, taken together, consists of three indexed publications identified through PubMed at time of writing. That is a thin evidentiary base. A careful reading of what each study design can and cannot establish is more useful to a working researcher than a summary that averages across them.
Kolosova et al., 2002 (PMID 12134478) — Injured nerve function, rodent model.[4] This study is the primary evidence for the neuroprotective framing that appears in most descriptions of Cortagen. The reported effect is delayed rather than acute, which is a specific and interesting finding: it implies either a transcriptional or a structural remodeling mechanism rather than a rapid receptor-mediated one. What the study cannot establish: the dose–response relationship (whether the effect is monotonic, saturating, or non-monotonic is not determinable from a single report), the durability of the observed restoration beyond the study window, and — critically — whether the effect generalises beyond the specific injury model used. No replication study was identified.
Zarubina & Shabanov, 2011 (PMID 21476278) — Chronic cerebral ischaemia, combination design.[5] The paired-agent design is the limiting factor here. Cortagen was administered alongside Cortexin, a polypeptide preparation of a different complexity class. Effect partitioning between the two agents is not possible from the published data. This study is admissible as evidence that a preparation containing Cortagen was associated with measurable outcomes in an ischaemia model; it is not admissible as evidence that Cortagen alone produced those outcomes. Researchers wishing to use this study as a foundation for single-agent work would need to design a factorial or dose-subtraction experiment to isolate the tetrapeptide's contribution.
Anisimov et al., 2004 (PMID 15159690) — Gene expression in mouse heart, microarray.[6] This is the methodologically most informative entry and the one that most directly challenges the tissue-specificity narrative. Microarray studies generate hypothesis-generating signal, not mechanistic proof: differential expression of a gene set in cardiac tissue following exposure to a cortex-classified tetrapeptide tells an investigator which pathways to interrogate next, not what the peptide's receptor is or how the transcriptional change is transduced. The study does not report binding data, does not identify a receptor, and does not establish whether the cardiac gene-expression changes are direct (AEDP acting on cardiac cells) or indirect (AEDP acting on another tissue whose output then reaches the heart). All three interpretations remain open. This ambiguity is not a flaw in the study — microarray studies are not designed to close mechanistic questions — but it means the cardiac finding should be read as a signal warranting further investigation, not as evidence of a defined cardiac effect.
Aggregate assessment. Three studies, each in a different model, each with a distinct design limitation, none replicated, none in humans. The honest characterisation of the Cortagen evidence base is: preliminary, rodent- and cell-culture-level signals suggesting possible effects on neural function and gene expression, with a methodologically important but mechanistically unresolved cardiac transcriptional finding. The tissue-specificity claim, as it applies to this compound, is not supported by the available data and is actively complicated by the 2004 microarray result. This is what the record contains. It is also, for a researcher designing the next experiment in this space, a relatively clear map of where the gaps are.
